Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.16, $0.23 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $111 million versus the consensus estimate of $101.83 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.